What the current evidence shows — the short answer

The available clinical data on ChondroFiller injection is consistent and encouraging — with one important caveat about where it comes from.

Across four prospective knee studies, patients reported functional score improvements of approximately 30 points on the IKDC scale — a measure running from 0 (severely limited) to 100 (fully active). That figure comfortably exceeds the Minimal Clinically Important Difference of 16.7 points, the threshold at which patients notice a meaningful change in daily life. In the most detailed of those studies — the Jerosch et al. post-market clinical follow-up — the mean improvement was 32.4 points, sustained at three years, with patients reaching an average functional score of around 80. On safety, reported complication rates sit at approximately 0% and reoperation rates at 3–8% across the available data.

Every piece of that published efficacy data derives from manufacturer-sponsored investigations and the manufacturer's own Clinical Evaluation Report (CER v09, April 2025). No independent randomised controlled trial exists. The ultrasound-guided outpatient injection pathway — the route delivered at the London Cartilage Clinic — is also a clinical evolution from the device's original surgically-studied form, meaning the injection-specific evidence base is newer and thinner than the headline trial figures alone suggest. The functional and safety signal is consistent across studies spanning up to three years; equally, patients considering this treatment are entitled to know that the evidence has not yet been independently verified.

How a ChondroFiller injection is meant to work

ChondroFiller is a CE-marked Class III medical device made from acid-extracted, murine-derived Type I collagen — and contains no living cells of its own. Once placed as an ultrasound-guided outpatient injection, the material gels rapidly inside the joint, forming a stable scaffold directly over the worn articular surface. That scaffold acts as a chemotactic matrix, drawing in the patient's own progenitor cells to produce new extracellular matrix — a process called matrix-induced chondrogenesis.

Hyaluronic acid supplements the joint's lubricating fluid but does not prompt structural tissue repair. Microfracture drills into subchondral bone to release marrow cells, though the tissue that forms is largely fibrocartilage — mechanically weaker than hyaline cartilage. ChondroFiller targets hyaline-like restoration through scaffold recruitment rather than marrow stimulation.

Because the injection coats the entire load-bearing articular surface rather than filling a discrete surgical cavity, MRI fill scores and functional outcomes such as IKDC are tracking scaffold maturation and surface coverage — not point-to-point defect filling. That distinction helps explain why MOCART scores in the clinical studies improve progressively over months rather than appearing complete on an early scan, and why patient-reported function is the primary signal in the available evidence.

Functional improvement: what the outcome scores show

Reaching a score of around 80 on the 100-point IKDC scale — the level patients in the Jerosch et al. post-market follow-up achieved at three years — typically corresponds to comfortable stair climbing, recreational cycling, and a return to light sport. The mean gain of 32.4 points carries extra weight because it is roughly double the Minimal Clinically Important Difference of 16.7: the point at which patients actually notice a change day-to-day, not just on paper.

MRI evidence adds a structural dimension to the functional picture. MOCART scoring maps defect fill and tissue integration on a 0–100 scale; values above 80 indicate greater than 80% defect filling with solid integration into the surrounding native cartilage. European studies using ChondroFiller injection returned MOCART readings of 81.6 to 84.3 — consistently clearing that threshold.

The trajectory matters as much as the endpoint. In one sub-study, MOCART stood at 65.3 at four weeks, rising to 81.6 at twelve months. That progressive pattern is practically significant: the scaffold continues to mature and consolidate well beyond the initial injection, so patients who feel slow early progress are not necessarily outside the expected course.

Defect sizes up to 6 cm² have been included in the clinical data, and the outpatient injection format removes the strict size and age ceilings that apply in some surgical protocols. Individual outcomes depend on joint condition, defect characteristics, and patient biology, so a specialist assessment is needed to judge expected response — but across the studied cohorts, the structural and functional signals are consistent.

Side effects and safety: what is and is not known

No serious adverse events have been reported in the manufacturer-sponsored studies of ChondroFiller injection, and the complication rate across available data stands at approximately 0%. The reoperation rate — covering cases where further intervention was required — sits at 3–8% across the studied cohorts.

For context, two commonly compared procedures carry considerably higher figures: microfracture has a reported reoperation rate of up to 41%, whilst ACI and MACI carry complication rates of up to 17% and reoperation rates of up to 37%. Those comparisons need a caveat: the data come from different study populations, different era registries, and different surgical contexts, so a like-for-like reading has limits. What they indicate is that the safety signal for ChondroFiller injection, as currently reported, is not unfavourable relative to established alternatives — not that risk has been ruled out.

A more specific gap applies to the injection route itself. The underlying clinical evidence was gathered in studies using arthroscopic placement; the safety profile of the ultrasound-guided outpatient injection pathway has not been independently validated, and all available data is sponsor-funded. That limitation should be weighed honestly alongside the reassuring event-rate figures.

Contraindications include:

• active infection in the target joint
• known allergy to murine or bovine collagen
• immunosuppression from any cause
• poorly controlled diabetes
• unrealistic expectations of immediate or guaranteed pain relief

A specialist assessment will clarify whether any of these factors apply before an injection course is considered.

The evidence gaps patients should factor in

Two scientific questions sit genuinely open at this stage of the evidence.

Collagen type. ChondroFiller injection is built on Type I collagen — the body's most abundant structural protein, found in dense connective tissue throughout the body. Articular hyaline cartilage is, however, primarily Type II collagen-dominant. The scaffold provides the architectural matrix; whether the repair tissue that forms within it achieves full long-term biomechanical equivalence to native hyaline cartilage has not yet been established, and research is ongoing.

Follow-up horizon. The longest available data runs to three years, from the Jerosch et al. post-market cohort. Three years is long enough to confirm that functional gains hold, but insufficient to address durability questions that matter most to patients in their forties or fifties — how the repair tissue performs at ten or fifteen years is currently unknown.

Both gaps exist alongside the sponsor-funded evidence base noted at the outset of this article, and the injection pathway's status as a clinical adaptation of a device whose CER data was gathered in a different delivery context. Neither is a disqualifying limitation, but together they define the honest boundary of what the current evidence can and cannot tell a prospective patient.

For Kellgren–Lawrence Grade III/IV osteoarthritis, the evidence base is thinner. Clinical discussion at that stage often involves a combination approach — ChondroFiller injection addressing the cartilage surface while Arthrosamid provides synovial cushioning. These act through separate mechanisms and are not a single blended product.

The procedure is self-funded in the UK, starting from approximately £3,000, with no NHS or private insurer coverage currently available.

Who is most likely to benefit and how to find out

Patients most likely to benefit, based on the available data, are those with a confirmed focal articular cartilage defect — broadly ICRS Grade II or III — where conservative management has not provided adequate relief and surgery is unwanted or not yet clinically indicated. The injection format imposes fewer age and defect-size restrictions than arthroscopic protocols; individual suitability still requires MRI and specialist review. Contraindications, covered in the safety section, narrow the eligible group further.

At the more advanced end of the OA spectrum (Kellgren–Lawrence Grade III–IV), assessment remains possible, though the clinical discussion at that stage typically involves a combination approach — ChondroFiller injection for the cartilage surface and Arthrosamid for synovial cushioning — with expectations calibrated accordingly.

The honest synthesis: available data supports careful optimism for suitable focal-defect patients willing to proceed on evidence that is consistent but sponsor-funded, carries a three-year follow-up maximum, and covers an injection pathway not yet independently validated. That is a reasonable basis for many patients in the right clinical situation; it is not a basis for confidence in all.

As with any image-guided scaffold procedure, placement technique influences how the material distributes and sets within the joint — a practical reason why provider experience carries clinical weight alongside product selection.

Liquid Cartilage™ is delivered in the UK as an ultrasound-guided outpatient injection at the London Cartilage Clinic on Harley Street, where Professor Paul Y. F. Lee leads the programme. Book an assessment via londoncartilage.com.

1. [1] Type I collagen. https://en.wikipedia.org/?curid=9267741 https://en.wikipedia.org/?curid=9267741
2. [2] Cartilage. https://en.wikipedia.org/?curid=166945 https://en.wikipedia.org/?curid=166945